drugset
drugset / Trial / NCT02755922

Bone Regeneration With Mesenchymal Stem Cells

NCT02755922 ↗

Phase 3 Completed 20 enrolled Mexican Social Security Institute
RandomizedParallel-groupSingle-blindTreatment

Summary

Mandible fractures are a common cause of facial injury in adults. The autologous mesenchymal stem cell (AMSC) transplantation, is proposed as an alternative to the conventional graft treatment, improving bone neoformation.The objective was to evaluate the effectiveness of AMSCs application in mandibular fractures to reduce regeneration time and increase bone quality.

Timeline

Start
2010-04
Primary completion
2010-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous mesenchymal stem cells Cell therapy — —

Indications

No indication recorded.